Rutgers, The State University of New Jersey
The goal of this clinical trial is to learn if intraosseous antibiotic (cefazolin) administration can improve antibiotic levels in adults undergoing primary total hip replacement. The main question it aims to answer is: • Does intraosseous cefazolin increase antibiotic concentrations in blood and tissue compared with standard intravenous cefazolin alone? Researchers will compare patients receiving intraosseous cefazolin plus standard intravenous cefazolin to those receiving placebo injection plus standard intravenous cefazolin to see if local antibiotic delivery improves outcomes. Participants will: * Receive standard intravenous cefazolin before surgery and either intraosseous cefazolin or placebo * Provide blood samples before and after antibiotic administration * Have small tissue samples collected during surgery * Complete routine postoperative follow-up and outcome assessment for 90 days
Inclusion Criteria: * Age ≥ 18 years * Scheduled to undergo primary total hip arthroplasty * Receiving standard institutional antibiotic prophylaxis with IV bolus cefazolin prior to surgery Exclusion Criteria: * Reduced renal function (GFR \< 30) * Reduced liver function (AST/ALT \> 3× upper limit of normal) * Weight \> 120 kg * Undergoing bilateral total hip arthroplasty * Documented cefazolin anaphylaxis * Active joint infection * History of diabetes * Inflammatory arthropathies * Inability to understand written and/or spoken English * Undergoing revision total hip arthroplasty
1 gram of ancef will be administered intra-osseously into the patient's operative side greater trochanter
normal saline
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.